Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 18 unusual trades.
Delving into the details, we found 61% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $237,017, and 14 were calls, valued at $927,628.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $90.0 for Viking Therapeutics during the past quarter.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale trades within a strike price range from $5.0 to $90.0 in the last 30 days.
Viking Therapeutics Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BULLISH | 04/05/24 | $90.00 | $254.7K | 7.4K | 1.0K |
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $12.00 | $106.0K | 139 | 20 |
| VKTX | CALL | SWEEP | BULLISH | 03/22/24 | $77.00 | $71.7K | 176 | 656 |
| VKTX | CALL | TRADE | BULLISH | 07/19/24 | $70.00 | $70.0K | 324 | 0 |
| VKTX | PUT | TRADE | NEUTRAL | 04/19/24 | $55.00 | $63.2K | 1.9K | 201 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Viking Therapeutics Standing Right Now?
- Currently trading with a volume of 716,356, the VKTX's price is down by -0.79%, now at $62.85.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 36 days.
Expert Opinions on Viking Therapeutics
In the last month, 5 experts released ratings on this stock with an average target price of $95.0.
- Reflecting concerns, an analyst from HC Wainwright & Co. lowers its rating to Buy with a new price target of $90.
- An analyst from BTIG persists with their Buy rating on Viking Therapeutics, maintaining a target price of $100.
- An analyst from Raymond James persists with their Outperform rating on Viking Therapeutics, maintaining a target price of $115.
- An analyst from HC Wainwright & Co. persists with their Buy rating on Viking Therapeutics, maintaining a target price of $90.
- In a cautious move, an analyst from Stifel downgraded its rating to Buy, setting a price target of $80.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
